← Compound Library

KPV

Anti-Inflammatory Tripeptide

Also known as: Lys-Pro-Val · Alpha-MSH(11-13)

A C-terminal tripeptide of alpha-MSH with potent anti-inflammatory activity via NF-kB inhibition. Used orally or by injection for gut inflammation & systemic inflammatory conditions.

Typical Dose

500 mcg–1 mg 2x/day (oral); 250–500 mcg 1–2x/day (SubQ)

Route

Oral (for gut) or subcutaneous injection (for systemic)

Cycle

4–8 weeks

Half-life

Short (tripeptide; rapidly cleared)

Storage

Lyophilized: room temp. Reconstituted: 2–8°C, use within 30 days.

Overview

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, corresponding to residues 11–13. Despite its minimal size, it retains the full anti-inflammatory activity of alpha-MSH via melanocortin receptor-independent inhibition of NF-kB signaling in inflammatory cells.

Its extremely small size allows oral bioavailability (unusual among peptides) — it resists GI degradation better than most peptides & can reach intestinal tissue after oral administration. This makes it uniquely useful for gut inflammation conditions (IBD, colitis) where targeted delivery to intestinal mucosa is desired. Systemic inflammation can also be addressed via SubQ injection.

Quick Start Guide

1

Oral: 500 mcg–1 mg dissolved in water, twice daily on empty stomach (gut-targeted).

2

SubQ: 250–500 mcg once or twice daily near site of inflammation.

Research Indications

Gut inflammation (IBD, colitis)

Most Effective

Oral bioavailability allows direct delivery to intestinal mucosa. Inhibits NF-kB in gut epithelial cells. Animal models of colitis show significant anti-inflammatory benefit.

Systemic inflammation

Effective

NF-kB inhibition across multiple tissue types. Broad anti-inflammatory without immunosuppression.

Skin inflammation

Moderate

Topical & injected KPV studied for psoriasis & wound healing. Reduces inflammatory cytokines at the site of application.

Research Protocols

Gut healing / IBD

4–8 weeks

Dose

500 mcg–1 mg

Frequency

Twice daily, fasted oral administration

Route

Oral (dissolved in water)

Systemic anti-inflammatory

4–8 weeks

Dose

250–500 mcg

Frequency

Once or twice daily SubQ

Route

SubQ near inflammation site

Peptide Interactions

BPC-157Synergistic

Both have gut repair & anti-inflammatory activity. BPC-157 drives epithelial repair via GH receptor upregulation; KPV inhibits NF-kB. Complementary mechanisms.

Side Effects & Safety

Common

  • Minimal. Well-tolerated in animal & limited human studies.

Uncommon

  • Mild injection site redness (SubQ route)

When to Stop

  • Signs of allergic reaction

How to Reconstitute

1

Reconstitute with water for oral use or BAC water for SubQ.

2

Oral: dissolve in 10–20 mL water & consume.

3

SubQ: standard reconstitution as with other peptides.

Dosing math: Very small peptide. Typical: 1 mL BAC water per 1–2 mg vial. Oral solution can be more dilute.

Quality Indicators

Good — use as normal

  • Clear, colorless solution

Discard immediately

  • Particulate
  • Discoloration

What to Expect

Week 1–2

Anti-inflammatory effect begins rapidly given NF-kB inhibition. IBD symptoms may begin to improve within days of oral administration.

Week 3–8

Continued gut mucosal healing (in IBD protocols). Systemic inflammatory markers improving.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Research References

KPV tripeptide inhibits NF-kB activation & produces anti-inflammatory effects in intestinal epithelial cells

Journal of Pharmacology & Experimental Therapeutics · 2005

Demonstrates oral bioavailability & NF-kB-mediated anti-inflammatory mechanism of KPV in gut tissue.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample